Essay --

Mid Term Assignment - GenzymeHIMP6170 professor Aditya PaiShweta Harwalkar (ID 212294831)2/13/2014 Company / portfolio for analysis (Refer to Appendix 1, 2, 3 & 4)Genzyme heap (Genzyme), a subsidiary of Sanofi-aventis, is a biotechnology company which is principally enmeshed in developing products and services for rare genetic disorders. The company has its operations worldwide with its principal concentration in the US and the UK. Genzyme is headquartered in Massachusetts, the US. The provoke company, Sanofi, is a global and diversified healthcare leader. Genzyme is currently organized into dickens business units Rare Diseases and Multiple Sclerosis.Rare Diseases Focusing on uncommon and underserved medical conditions, the Rare Disease business unit is currently concentrate on three medical areasGenetic Diseases - Pioneering Solutions to Lysosomal Storage Disorders Orphan drugsEndocrinology - genetically engineered version of thyroid-stimulating hormone (TSH)Cardiovascula r Disease - inherited disorders, such as familial hypercholesterolemia, a genetic and potentially life-threatening form of sternly high cholesterol that often doesnt respond to traditional treatmentsMultiple induration Multiple sclerosis is a chronic unsoundness that affects each soul differently, with symptoms ranging from numbness in the limbs or forgetfulness to paralysis or loss of vision. Revenues and step-up trends(Refer to Appendix 5)Sanofi acquired Genzyme for $20.1 billion. New Genzyme was successfully integrated resulting in sales offshoot of 16.9%. Sales for Fabrazyme (agalsidase beta), a treatment for Fabry disease, nearly doubled. Sales for Myozyme and Lumizyme (alglucosidase alfa), indicated in Pompe d... ...better compensationsShareholdersA leader in orphan drug commercialise will sop up more shareholdersGenzyme must increase economic value created for shareholdersRetail imprisonmentReducing the retail chain can help Genzyme sell at decline price or have hig her expediencyChanges in the retail chain system will probably affect the profit margin of the drugGovernmentWork closely with the government to convey sure that the orphan drugs are available in that country/marketGovernment regulates the price of drugs - If Genzyme does not lower the cost of orphan drugs, so it is very likely that government will set a lower price, which will cut Genzymes profitOther rare disease associationsCommunicate effectively and work closely with these rare disease associations close to rare diseases do not have treatment available - high up pricing will prevent some patients from getting treatment